Swiss biotech Windward Bio files for Nasdaq IPO to fund China-derived assets and in-house R&D

Basel-based Windward Bio filed for Nasdaq IPO as $WWB, advancing WIN378 and WIN027 from Kelun-Biotech, Harbour BioMed, and Qyuns for asthma, COPD, and eczema. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing:…

Kyle LaHucik · 2026-10-23

A 2-year-old European biotech with two clinical-stage assets from China is the latest to attempt an initial public offering in the US. Basel-based Windward Bio submitted its cards for a Nasdaq ...

Source: Endpoints News